Profile data is unavailable for this security.
About the company
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
- Revenue in USD (TTM)82.50m
- Net income in USD-108.86m
- Incorporated2014
- Employees335.00
- LocationPoseida Therapeutics Inc9390 TOWNE CENTRE DRIVE, SUITE 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 779-3100
- Fax+1 (302) 636-5454
- Websitehttps://poseida.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc | 354.00k | -83.09m | 246.61m | 39.00 | -- | 5.05 | -- | 696.62 | -25.73 | -25.73 | 0.1182 | 4.09 | 0.002 | -- | -- | 50,571.43 | -34.17 | -34.98 | -40.05 | -37.92 | -- | -- | -16,901.98 | -971.76 | -- | -- | 0.2039 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 248.48m | 122.00 | -- | 2.37 | -- | 346.53 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 250.36m | 135.00 | -- | -- | -- | 4.86 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 253.76m | 50.00 | -- | 1.90 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 255.37m | 14.00 | -- | 2.87 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -14.53m | 258.33m | 9.00 | -- | 2.31 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Sanara Medtech Inc | 68.00m | -4.89m | 259.27m | 107.00 | -- | 5.99 | -- | 3.81 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 260.67m | 449.00 | -- | 10.69 | -- | 14.20 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 260.82m | 335.00 | -- | 3.08 | -- | 3.16 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 261.85m | 123.00 | -- | 9.36 | -- | 6.84 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Cibus Inc | 2.32m | -285.67m | 267.62m | 183.00 | -- | 0.8188 | -- | 115.35 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 273.43m | 145.00 | -- | 1.65 | -- | 3.75 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 276.51m | 275.00 | -- | 0.5063 | -- | 0.9966 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Data as of Jun 10 2024. Currency figures normalised to Poseida Therapeutics Inc's reporting currency: US Dollar USD
38.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 14.45m | 14.98% |
| Pentwater Capital Management LPas of 31 Mar 2024 | 5.98m | 6.19% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.29m | 4.45% |
| SilverArc Capital Management LLCas of 31 Mar 2024 | 3.60m | 3.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.32m | 3.44% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.56m | 1.62% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.45m | 1.50% |
| Aisling Capital Management LPas of 31 Mar 2024 | 1.04m | 1.08% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 965.05k | 1.00% |
| Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 830.13k | 0.86% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
